Cancer antigen 125 in patients with chronic liver disease

Harshad Devarbhavi, Dorothy Kaese, Amy W. Williams, Jorge Rakela, George G. Klee, Patrick Sequeira Kamath

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objectives: To determine the association between elevated levels of serum cancer antigen (CA) 125 and liver disease and to explore the possibility that CA 125 is produced by the peritoneum as a nonspecific response to the presence of fluid in the peritoneal cavity. Patients and Methods: Between June and October 1992, CA 125 levels were measured in serum stored from 50 consecutive patients with cirrhotic ascites, 20 patients with cirrhosis but without ascites, and 12 patients with acute viral hepatitis without ascites. Serum CA 125 was also measured in 4 patients with chronic renal failure before and after initiation of continuous ambulatory peritoneal dialysis. Results: Levels of CA 125 were elevated in patients with all forms of liver disease, especially in those with cirrhotic ascites irrespective of the etiology of cirrhosis or the presence of spontaneous bacterial peritonitis or hepatocellular carcinoma. Levels of CA 125 did not change significantly 1 month after initiation of continuous ambulatory peritoneal dialysis. Conclusion: Cancer antigen 125 is elevated in patients with acute and chronic liver disease, especially in those with cirrhotic ascites. This elevation in CA 125 is not because of a nonspecific response of the peritoneum to fluid in the peritoneal cavity. Awareness of the association of elevated CA 125 in patients with cirrhotic ascites can prevent unnecessary surgical intervention.

Original languageEnglish (US)
Pages (from-to)538-541
Number of pages4
JournalMayo Clinic Proceedings
Volume77
Issue number6
StatePublished - 2002

Fingerprint

Liver Diseases
Chronic Disease
Ascites
Antigens
Neoplasms
Continuous Ambulatory Peritoneal Dialysis
Peritoneum
Peritoneal Cavity
Fibrosis
Serum
Peritonitis
Hepatitis
Chronic Kidney Failure
Hepatocellular Carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Devarbhavi, H., Kaese, D., Williams, A. W., Rakela, J., Klee, G. G., & Kamath, P. S. (2002). Cancer antigen 125 in patients with chronic liver disease. Mayo Clinic Proceedings, 77(6), 538-541.

Cancer antigen 125 in patients with chronic liver disease. / Devarbhavi, Harshad; Kaese, Dorothy; Williams, Amy W.; Rakela, Jorge; Klee, George G.; Kamath, Patrick Sequeira.

In: Mayo Clinic Proceedings, Vol. 77, No. 6, 2002, p. 538-541.

Research output: Contribution to journalArticle

Devarbhavi, H, Kaese, D, Williams, AW, Rakela, J, Klee, GG & Kamath, PS 2002, 'Cancer antigen 125 in patients with chronic liver disease', Mayo Clinic Proceedings, vol. 77, no. 6, pp. 538-541.
Devarbhavi H, Kaese D, Williams AW, Rakela J, Klee GG, Kamath PS. Cancer antigen 125 in patients with chronic liver disease. Mayo Clinic Proceedings. 2002;77(6):538-541.
Devarbhavi, Harshad ; Kaese, Dorothy ; Williams, Amy W. ; Rakela, Jorge ; Klee, George G. ; Kamath, Patrick Sequeira. / Cancer antigen 125 in patients with chronic liver disease. In: Mayo Clinic Proceedings. 2002 ; Vol. 77, No. 6. pp. 538-541.
@article{f30b968d52984dda9f0e2a5eac63210f,
title = "Cancer antigen 125 in patients with chronic liver disease",
abstract = "Objectives: To determine the association between elevated levels of serum cancer antigen (CA) 125 and liver disease and to explore the possibility that CA 125 is produced by the peritoneum as a nonspecific response to the presence of fluid in the peritoneal cavity. Patients and Methods: Between June and October 1992, CA 125 levels were measured in serum stored from 50 consecutive patients with cirrhotic ascites, 20 patients with cirrhosis but without ascites, and 12 patients with acute viral hepatitis without ascites. Serum CA 125 was also measured in 4 patients with chronic renal failure before and after initiation of continuous ambulatory peritoneal dialysis. Results: Levels of CA 125 were elevated in patients with all forms of liver disease, especially in those with cirrhotic ascites irrespective of the etiology of cirrhosis or the presence of spontaneous bacterial peritonitis or hepatocellular carcinoma. Levels of CA 125 did not change significantly 1 month after initiation of continuous ambulatory peritoneal dialysis. Conclusion: Cancer antigen 125 is elevated in patients with acute and chronic liver disease, especially in those with cirrhotic ascites. This elevation in CA 125 is not because of a nonspecific response of the peritoneum to fluid in the peritoneal cavity. Awareness of the association of elevated CA 125 in patients with cirrhotic ascites can prevent unnecessary surgical intervention.",
author = "Harshad Devarbhavi and Dorothy Kaese and Williams, {Amy W.} and Jorge Rakela and Klee, {George G.} and Kamath, {Patrick Sequeira}",
year = "2002",
language = "English (US)",
volume = "77",
pages = "538--541",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Cancer antigen 125 in patients with chronic liver disease

AU - Devarbhavi, Harshad

AU - Kaese, Dorothy

AU - Williams, Amy W.

AU - Rakela, Jorge

AU - Klee, George G.

AU - Kamath, Patrick Sequeira

PY - 2002

Y1 - 2002

N2 - Objectives: To determine the association between elevated levels of serum cancer antigen (CA) 125 and liver disease and to explore the possibility that CA 125 is produced by the peritoneum as a nonspecific response to the presence of fluid in the peritoneal cavity. Patients and Methods: Between June and October 1992, CA 125 levels were measured in serum stored from 50 consecutive patients with cirrhotic ascites, 20 patients with cirrhosis but without ascites, and 12 patients with acute viral hepatitis without ascites. Serum CA 125 was also measured in 4 patients with chronic renal failure before and after initiation of continuous ambulatory peritoneal dialysis. Results: Levels of CA 125 were elevated in patients with all forms of liver disease, especially in those with cirrhotic ascites irrespective of the etiology of cirrhosis or the presence of spontaneous bacterial peritonitis or hepatocellular carcinoma. Levels of CA 125 did not change significantly 1 month after initiation of continuous ambulatory peritoneal dialysis. Conclusion: Cancer antigen 125 is elevated in patients with acute and chronic liver disease, especially in those with cirrhotic ascites. This elevation in CA 125 is not because of a nonspecific response of the peritoneum to fluid in the peritoneal cavity. Awareness of the association of elevated CA 125 in patients with cirrhotic ascites can prevent unnecessary surgical intervention.

AB - Objectives: To determine the association between elevated levels of serum cancer antigen (CA) 125 and liver disease and to explore the possibility that CA 125 is produced by the peritoneum as a nonspecific response to the presence of fluid in the peritoneal cavity. Patients and Methods: Between June and October 1992, CA 125 levels were measured in serum stored from 50 consecutive patients with cirrhotic ascites, 20 patients with cirrhosis but without ascites, and 12 patients with acute viral hepatitis without ascites. Serum CA 125 was also measured in 4 patients with chronic renal failure before and after initiation of continuous ambulatory peritoneal dialysis. Results: Levels of CA 125 were elevated in patients with all forms of liver disease, especially in those with cirrhotic ascites irrespective of the etiology of cirrhosis or the presence of spontaneous bacterial peritonitis or hepatocellular carcinoma. Levels of CA 125 did not change significantly 1 month after initiation of continuous ambulatory peritoneal dialysis. Conclusion: Cancer antigen 125 is elevated in patients with acute and chronic liver disease, especially in those with cirrhotic ascites. This elevation in CA 125 is not because of a nonspecific response of the peritoneum to fluid in the peritoneal cavity. Awareness of the association of elevated CA 125 in patients with cirrhotic ascites can prevent unnecessary surgical intervention.

UR - http://www.scopus.com/inward/record.url?scp=0036260570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036260570&partnerID=8YFLogxK

M3 - Article

C2 - 12059123

AN - SCOPUS:0036260570

VL - 77

SP - 538

EP - 541

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -